ONCY

Business Context and Reporting Period

Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year Ended December 31, 2003 (Information Circular dated April 22, 2004; Meeting Date May 26, 2004)
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of oncolytic viruses, specifically REOLYSIN^® (a formulation of the human reovirus), for the treatment of Ras-mediated cancers. The company has not generated significant operating revenues and expects to continue incurring losses until commercialization.

Key Financial Metrics (Year Ended Dec 31, 2003)

Note: Revenue consists entirely of interest income and income from short-term investments. There were no operating revenues from product sales.

Material Changes vs. Prior Period

• Increased Net Loss: The 2003 net loss increased by approximately 40% compared to 2002. This was primarily driven by a one-time net loss of $1,892,232 from the sale of investments (Transition Therapeutics Inc. and BCY LifeSciences Inc.) and an increase in stock-based compensation expense due to a change in accounting policy.
• Significant Capital Raise: The company raised approximately $19 million in 2003 through three private placements, one public offering, and the exercise of options/warrants. This increased total liquid assets from $8.3 million in 2002 to $20.8 million in 2003.
• Investment Portfolio Changes: The company sold its entire stake in Transition Therapeutics Inc. (TTH) for a loss and partially sold its stake in BCY LifeSciences Inc. (BCY) for a gain. Remaining investments in BCY were valued at $157,140 at year-end.
• Accounting Policy Change: Effective January 1, 2003, the company adopted the fair value method for stock-based compensation (CICA Handbook), increasing reported expenses by $812,711 compared to the intrinsic value method used previously.
• R&D Expense Shift: Total R&D expenses decreased to $3.3 million from $4.3 million in 2002. This reduction was due to the completion of the manufacturing process development phase in 2002, shifting focus in 2003 to production runs and securing raw materials.

Guidance, Outlook, and Risks

Management Commentary & Outlook

• Clinical Progress: Management reported positive interim results for recurrent malignant glioblastoma and T2 prostate cancer trials. A collaboration with the U.S. National Cancer Institute (NCI) was announced to conduct multiple clinical trials, with the NCI bearing trial expenses while Oncolytics provides the drug.
• Manufacturing: The company completed the development of a manufacturing process for REOLYSIN^® and established independent viral and cell banks to reduce reliance on third-party suppliers.
• Liquidity: Management believes current capital resources ($20.8 million) are adequate to fund operations and clinical trials into 2006.
• Future Financing: The company seeks shareholder approval for future private placements of up to 50% of issued and outstanding shares to bypass TSX 25% rules and secure working capital.

Risks and Contingencies

• Development Risk: As a development-stage company, there is no assurance that REOLYSIN^® will prove safe or effective in humans or receive regulatory approval (FDA/Health Canada).
• Product Liability: The company currently has no product liability insurance, which could inhibit commercialization if a claim arises.
• Regulatory & Manufacturing: Dependence on a single U.S. supplier for manufacturing poses a risk of disruption. Regulatory approval processes are lengthy, expensive, and uncertain.
• Financial Sustainability: The company has an accumulated deficit of nearly $25 million and expects to continue incurring significant losses. Future profitability depends entirely on successful commercialization.
• Contingent Obligations: A $1.0 million milestone payment is due to founding shareholders upon receipt of marketing approval for REOLYSIN^®. Additional royalties (2.85% of net sales) may be payable upon commercialization.

Investor Verification Checklist

• Cash Runway: Verify if the $20.8 million in liquid assets is sufficient to fund the planned systemic administration trials and manufacturing scale-up through 2006 without further dilution.
• Investment Sales Impact: Confirm the non-cash nature of the $1.9 million loss on investment sales and its impact on the reported net loss versus cash burn.
• Stock-Based Compensation: Review the assumptions used in the Black-Scholes model (volatility, hold period) for the new fair value accounting method, as these significantly impact reported expenses.
• Private Placement Authority: Assess the implications of the proposed 50% private placement authority on existing shareholder dilution.
• Manufacturing Independence: Verify the status of the new viral/cell banks and the timeline for reducing dependence on the single U.S. contract manufacturer.
• Contingent Liabilities: Monitor the status of the $1.0 million milestone payment obligation tied to regulatory approval.